http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells
-
Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs
-
Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
-
Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
-
Lineage Cell Therapeutics (LCTX) Announces OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy
-
OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy
-
Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021
-
Lineage (LCTX) Announces Appointment of Dr. Dipti Amin to Its Board of Directors
-
Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors
-
Lineage Cell Therapeutics (LCTX) Announces Worldwide License Agreement With Immunomic Therapeutics for Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform
-
Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy
-
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform
-
OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD
-
Lineage Cell Therapeutics (LCTX) Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate Use
-
Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate Use
-
Lineage Cell Therapeutics (LCTX) Presents Additional Interim Data on OpRegen for Dry AMD With Geographic Atrophy
-
Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy
-
Lineage to Present at the Benzinga Global Biotech Small Cap Conference on March 24, 2021
-
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics (LCTX) Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering
-
Lineage Cell Therapeutics Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering
-
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
-
Lineage to Present at the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021
-
Lineage to Host Virtual OPC1 Investor & Analyst Day on February 22, 2021
-
Lineage Enters Into Exclusive Agreement with Neurgain Technologies to Evaluate Novel Delivery System for OPC1 to Treat Spinal Cord Injury
-
Lineage Posts Series of Webinars Highlighting Recent Progress With its Three Clinical-Stage Allogeneic Cell Transplant Programs
-
Lineage Cell Therapeutics (LCTX) CFO to Depart
-
Lineage Cell Therapeutics Announces Change to Executive Team
-
Lineage Cell Therapeutics Provides End of Year Shareholder Letter
-
Lineage Cell Therapeutics to Present at the 13th Annual LD Micro Main Event Conference on December 14, 2020
-
Lineage Cell Therapeutics (LCTX) Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury
-
Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury
-
AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics Presents New OpRegen® Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting
-
Lineage Cell Therapeutics Proudly Supports Patients’ Access to Innovative Cell Therapy Treatments and Research Through Passage of Proposition 14
-
Lineage Cell Therapeutics Completes Patient Enrollment in Phase 1/2a Clinical Study of OpRegen® Cell Therapy for the Treatment of Dry Age-related Macular Degeneration
-
Lineage Cell Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics to Host Expert Call Following OpRegen® Data Update at 2020 American Academy of Ophthalmology Meeting
-
AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome
-
Lineage Cell Therapeutics to Report Third Quarter 2020 Financial Results and Provide Business Update on November 4, 2020
-
OpRegen Data Update to Be Featured in Presentation by Christopher D. Riemann, MD at 2020 American Academy of Ophthalmology Meeting
-
Lineage Cell Therapeutics (LCTX) and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer
-
Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer
-
Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020
-
Lineage Cell Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and at Cantor Virtual Global Healthcare Conference on September 17, 2020
-
AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes
-
Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes
-
Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority for Development of a Bio-Retinal Patch for Treatment of Retinal Diseases in Partnership With Precise Bio
-
Lineage Cell Therapeutics (LCTX) Receives $24.6 Million Payment From Juvenescence Ltd.
-
Lineage Cell Therapeutics Receives $24.6 Million Payment From Juvenescence Ltd.

